Aripiprazole Lauroxil
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Dec 1, 2015 → Jul 11, 2017
NCT ID
NCT02634320About Aripiprazole Lauroxil
Aripiprazole Lauroxil is a approved stage product being developed by Alkermes for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02634320. Target conditions include Schizophrenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05662306 | Approved | Terminated |
| NCT02636842 | Phase 1 | Completed |
| NCT02634320 | Approved | Completed |
| NCT02320032 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia